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Purpose of the study
Real world data on the development of drug resistance
after virologic failure (VF) on a protease inhibitor (PI)-
based antiretroviral (ARV) regimen are limited. The
I50L substitution in protease is the primary mutation
associated with atazanavir drug resistance. The primary
objective was to compare the prevalence of I50L from
VF patients on an unboosted atazanavir (ATV)-based
regimen vs. those on a ritonavir-boosted ATV (ATV/r)-
based regimen regardless of prior treatment history.
Methods
IMPACT is a large cross-sectional study of patients with
VF while on an atazanavir-containing regimen that was
conducted at 220 sites in 8 countries. Demographic/
medical information and blood for a genotype resistance
test were collected at a single study visit. A substudy
evaluated the efficacy of the regimen subsequent to the
atazanavir-containing regimen based on when atazanavir
was used in therapy.
Summary of results
IMPACT enrolled 703 patients, and genotype resistance
tests were able to be performed for 678. 67 had been on
both ATV and ATV/r, and 55 had incomplete ARV his-
tories. Overall, 48/556 evaluable patients had virus with
an I50L: 12/96 (12.5%) on ATV and 36/460 (7.83%) on
ATV/r (p=0.116). Most patients had been on another PI
prior to atazanavir.
88/678 patients were on atazanavir (either ATV or
ATV/r) as a first PI, and 69 had a complete ARV his-
tory. 3/19 (15.8%) who started ATV and 5/50 (10%)
who started ATV/r had an I50L at VF. Phenotype resis-
tance tests were performed for these patients: 55 tests
showed full susceptibility while 12 tests showed reduced
susceptibility to atazanavir. The viral isolates from these
12 patients remained fully sensitive to both lopinavir
and darunavir.
Enrollment for the substudy was below the target
enrollment, and sample sizes in all of the comparison
groups were too small for meaningful statistical
inference.
Conclusions
In a large clinical cohort of subjects failing atazanavir-
based therapy with resistance data, I50L is uncommon
in subjects with VF on atazanavir. Most PI-naive sub-
jects failing an atazanavir-based regimen failed with
virus susceptible to atazanavir, and all viral isolates were
sensitive to the other PIs commonly used to treat virus
with PI drug resistance. These real world data provide
further support of clinical trial data that have shown
preservation of treatment options after VF when ataza-
navir is used as a first PI.
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